Difference between revisions of "SPECT Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
Line 11: Line 11:
 
*quantifying organs, like the liver, for dosimetry as potential use cases
 
*quantifying organs, like the liver, for dosimetry as potential use cases
  
−
'''Established Task Forces currently working toward a first Profile titled:
+
'''Established Task Forces''' currently working toward a first Profile titled: <font color=blue>''Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease''</font>   
−
 
−
<font color=blue>''Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease''</font>   
 
  
 
* Image Acquisition and Image Processing for DaTscan – ''Dr. Dewaraja''
 
* Image Acquisition and Image Processing for DaTscan – ''Dr. Dewaraja''

Revision as of 20:28, 17 March 2017

Co-chairs: Yuni Dewaraja, PhD; P. David Mozley, MD; John Seibyl, MD
Secretary: Julie Lisiecki
Roster: (Roster)

Project Snapshot

The SPECT Biomarker Committee seeks to develop a quantitative imaging profile for SPECT imaging.

Under consideration:

  • quantifying a small structure (like the basal ganglion in the DaTscan, thyroid)
  • quantifying organs, like the liver, for dosimetry as potential use cases

Established Task Forces currently working toward a first Profile titled: Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease

  • Image Acquisition and Image Processing for DaTscan – Dr. Dewaraja
  • Quantitative / Image Analysis – Drs. Miyaoka and Seibyl
  • Phantoms / DRO Group – Drs. Dickson and Zimmerman
  • Clinical / Literature Review – Dr. Seibyl

Meetings/Call Summaries

Literature Review (Profile 1.0)

Profile Development

Reference Materials


Retrieved from "https://qibawiki.rsna.org/index.php?title=SPECT_Biomarker_Ctte&oldid=11058"